How to Buy Coherus Oncology Stock
Coherus Oncology Inc
Coherus Oncology, Inc. , a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Coherus Oncology stock last closed at $1.22, up 5.17% from the previous day, and has decreased 28.65% in one year. It has overperformed other stocks in the Biotechnology industry by 0.21 percentage points. Coherus Oncology stock is currently +71.83% from its 52-week low of $0.71, and -35.45% from its 52-week high of $1.89.
At the moment, there are 120.87M CHRS shares outstanding. The market cap of CHRS is $147.46M. In the past 24 hours, 991,000 CHRS shares were traded.
How to Buy Coherus Oncology Stock
Not sure how to invest in Coherus Oncology stock? Here's how.
- Figure out where to buy Coherus Oncology stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you choose where to buy Coherus Oncology stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Choose your method of payment and add your information.
- Evaluate Coherus Oncology stock: The Coherus Oncology ticker symbol is CHRS. Is Coherus Oncology stock a good investment? Should you buy shares of CHRS? How do CHRS's underlying business fundamentals look? Do top analysts think Coherus Oncology is a good buy? Why has CHRS's stock price moved recently? (Hint: Our stock research website can help you evaluate if CHRS is a good stock to buy).
- Make your CHRS trade: Decide if you will purchase CHRS shares at the current market price or use a limit order to buy CHRS shares at a particular price.
- Keep tabs on your investment in CHRS: Create a watchlist to key updates about your position in Coherus Oncology shares.
Step 1: Figure out where to buy Coherus Oncology stock
You need a brokerage account in order to access the NASDAQ market and buy CHRS stock.
Our preferred brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Energy, New York to Hong Kong (for US users, only US stocks are available) ā you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen the right brokerage, the next step is to fill out some personal information so you are able to buy CHRS stock today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create your new trading account.
- Send your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have filled out your info on the greatest app to buy stocks, your next step is to transfer the money for your investment:
Check out the tutorial below to see the process of transferring funds into your investment account.
Step 4: Evaluate Coherus Oncology stock
Once you have decided on the best place to buy Coherus Oncology stock, it's absolutely critical to analyze their stock before you invest, so you truly wrap your head around the risk and upside.
Coherus Oncology Numbers
Coherus Oncology Due Diligence Checks
WallStreetZen was designed to help part-time investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CHRS's stock page.
Is CHRS stock undervalued or overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge CHRS's true value.
Using relative valuations measures:
- CHRS may be undervalued based on its P/E ratio of 0.92x, relative to Biotechnology industry P/E ratio of 203.58x
- CHRS may be undervalued based on its P/B ratio of 1.68x, relative to Biotechnology industry P/B ratio of 5.27x
You can do additional valuation research on CHRS's stock here.
CHRS Financial Overview
Pros:
- There are more short-term assets than short-term liabilities on the CHRS balance sheet.
- CHRS has cash burn of 90189000. It has enough cash and short-term investments to cover this for at least one year.
- CHRS profit margin has gone up from -0.4% to 185.4% in the past year.
- CHRS has $191.66M in cash and short term investments. This is sufficient to cover its annual cash burn of $90.19M.
- There are more short-term assets than long-term liabilities on the CHRS balance sheet.
Cons:
- Total CHRS debt is higher than 5 years ago, relative to shareholder equity.
- CHRS has a relatively high debt to equity ratio of 4.89.
Is it a good time to buy CHRS stock, according to Wall Street analysts?
Out of 1 Equities analysts who track CHRS, the consensus analyst rating on Coherus Oncology is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
You can dive deeper into what analysts are projecting on the Coherus Oncology stock forecast page.
CHRS Trading Indicators
CHRS Growth Metrics
Last year, CHRS earnings were $154.97M. Over the past 5 year, CHRS's earnings have grown by -10.22% per year. This was slower than the Biotechnology industry average of 10.77%.
Last year, CHRS revenue was $83.57M. During the past five year, CHRS's revenue has grown by -29.77% per year. This was slower than the Biotechnology industry average of 43.81%.
Dive into CHRS's earnings and revenue performance here.
Are CHRS executives and large shareholders buying or selling the stock?
In the past year, insiders at CHRS have sold more shares than they have bought.
Mats Wahlstrom, Director of CHRS, was the latest CHRS insider to sell. They sold $73,891.13 worth of CHRS shares on May 23, 2025.
Dig into more about who owns CHRS shares here.
Does CHRS stock generate passive income?
No, Coherus Oncology doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Make your CHRS trade
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly sufficient. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a given price, place a limit order.
Press the Open button and your broker will place the order.
If you want additional assistance buying stocks on eToro, watch the helpful video below:
Step 6: Keep tabs on your investment in CHRS
Now that you own some CHRS stock, you'll want to stay up-to-date on your new investment.
Put CHRS on a watchlist to get notified of the latest news about your CHRS stock.
CHRS Feed
How to Buy Stock in Coherus Oncology
To reiterate, here are the 6 steps for buying Coherus Oncology stock:
- Figure out where to buy Coherus Oncology stock
- Sign up for your brokerage account
- Deposit funds into your investment account
- Evaluate Coherus Oncology stock
- Make your CHRS trade
- Keep tabs on your investment in CHRS
If you are looking for a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you want to get notifications regarding your new investment in Coherus Oncology, click the button below.
Related "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.